Related Experiment Videos
P53 expression in stage I squamous cell lung cancer
J Moldvay1, J Strausz, M Egerváry
1National Korányi Institute of Pulmonology, Department of Bronchology, Budapest, Hungary. moldvay@toledo.koranyi.hu
Pathology Oncology Research : POR
|April 29, 1998
Summary
p53 protein positivity in early-stage squamous cell lung cancer indicates more aggressive tumors and shorter survival times. This finding aids in predicting patient outcomes and guiding treatment strategies for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Squamous cell lung cancer (SCLC) is a major global health concern.
- Understanding prognostic markers is crucial for early-stage SCLC management.
- The role of p53 protein in SCLC prognosis requires further elucidation.
Purpose of the Study:
- To investigate the correlation between p53 expression and patient survival in early-stage SCLC.
- To determine if p53 immunopositivity is a prognostic indicator in surgically treated SCLC patients.
Main Methods:
- Immunohistochemistry was used to assess p53 expression in 94 surgically treated stage I SCLC patients.
- Follow-up analysis was conducted to evaluate survival rates.
- Flow cytometry was employed to analyze DNA content in a subset of samples.
Main Results:
- Overall p53 positivity was observed in 48/94 patients.
- A significant correlation was found between p53 immunopositivity and reduced survival time (p=0.0125).
- Patients with p53-positive tumors had a mean survival time of 17.5 months, compared to 23.1 months for p53-negative tumors.
Conclusions:
- p53 positivity may serve as an indicator of aggressive tumor behavior in early-stage SCLC.
- This finding suggests p53 status could aid in predicting survival outcomes.
- No correlation was found between p53 status, prognosis, and DNA content via flow cytometry.